Taniguchi Hiroaki, Imai Kohzoh
The Section of Antibody, Vaccine and Molecular Targeted Therapy Research, Institute of Medical Science, University of Tokyo.
Nihon Rinsho. 2012 Dec;70(12):2087-92.
Monoclonal antibodies have become the most effective therapeutic modality for treating human cancer. Anti-cancer monoclonal antibodies can be targeted against cancer cells by several mechanisms. Even unconjugated antibodies show significant efficacy in the treatment of solid tumors and hematological malignancies. Immunoconjugates composed of antibodies conjugated to chemo-drugs, radioactive or toxins are powerful therapy for lymphomas and solid tumors. Moreover, immunomodulatory antibodies can promote the induction of anti-tumor immune responses by directly activating or inhibiting molecules of the immune system. Antibody structures now can be readily manipulated to facilitate selective interaction between the immune system and cancer cells, so that these reagents will become important components of the anti-neoplastic protocols of the future.
单克隆抗体已成为治疗人类癌症最有效的治疗方式。抗癌单克隆抗体可通过多种机制作用于癌细胞。即使是未偶联的抗体在实体瘤和血液系统恶性肿瘤的治疗中也显示出显著疗效。由与化疗药物、放射性物质或毒素偶联的抗体组成的免疫偶联物是治疗淋巴瘤和实体瘤的有力手段。此外，免疫调节抗体可通过直接激活或抑制免疫系统分子来促进抗肿瘤免疫反应的诱导。现在可以很容易地对抗体结构进行操控，以促进免疫系统与癌细胞之间的选择性相互作用，因此这些试剂将成为未来抗肿瘤方案的重要组成部分。
